Stocks · News reference

Bruker Affirms FY2026 Adj EPS Guidance of $2.10-$2.15 vs $2.12 Est; Lowers FY2026 Sales Guidance from $3.570B-$3.600B to $3.540B-$3.570B vs $3.589B Est

Aug 4, 2026, 11:05 AMBenzinga Newsdesk

Bruker (NASDAQ:BRKR) affirms FY2026 Adj EPS guidance from $2.10-$2.15 to $2.10-$2.15 vs $2.12 analyst estimate. Lowers FY2026 sales outlook from $3.570 billion-$3.600 billion to $3.540 billion-$3.570 billion vs $3.589

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

BRKR

Source: benzinga
Observed: Aug 4, 2026, 11:05 AM
Checked: Aug 4, 2026, 11:05 AM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaSep 4, 2026, 7:51 AMBenzinga Newsdesk
Bruker, Luvata Team Up To Boost Superconductor Supply For Fusion Power Projects
Bruker Energy & Supercon Technologies (BEST), a segment of Bruker Corporation (NASDAQ:BRKR), and Luvata Materials & Solutions, a Business Unit of Luvata Group (LUVATA) today announced a strategic collaboration
BRKR
BenzingaAug 31, 2026, 5:47 PMVandana Singh
Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit
10x Genomics won a $4.8 million patent infringement lawsuit against Qiagen subsidiary Parse Biosciences, prompting plans for an injunction.
BRKR QGEN TXG
BenzingaAug 11, 2026, 11:05 AMBenzinga Newsdesk
Bruker Announces Expanded Strategic Collaboration With And Minority Investment In Self-Driving Labs Firm Atinary Technologies; Terms Not Disclosed
BRKR
BenzingaAug 10, 2026, 2:54 PMBenzinga Newsdesk
Bruker shares are trading higher after the company announced a majority investment in MIMETAS to expand its post‑genomic solutions and advance drug discovery through microphysiological systems.
BRKR

Bruker Affirms FY2026 Adj EPS Guidance of $2.10-$2.15 vs $2.12 Est; Lowers FY2026 Sales Guidance from $3.570B-$3.600B to $3.540B-$3.570B vs $3.589B Est

Connected Markets

Related Headlines

Bruker, Luvata Team Up To Boost Superconductor Supply For Fusion Power Projects

Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit

Bruker Announces Expanded Strategic Collaboration With And Minority Investment In Self-Driving Labs Firm Atinary Technologies; Terms Not Disclosed

Bruker shares are trading higher after the company announced a majority investment in MIMETAS to expand its post‑genomic solutions and advance drug discovery through microphysiological systems.